Rhythm Pharmaceuticals (RYTM) Capital Leases (2019 - 2022)

Rhythm Pharmaceuticals (RYTM) has 4 years of Capital Leases data on file, last reported at $1.8 million in Q1 2022.

• On a quarterly basis, Capital Leases fell 25.98% year-over-year to $1.8 million in Q1 2022; TTM through Mar 2022 was $1.8 million, a 25.98% decrease from a year earlier, with the FY2021 full-year figure at $1.9 million, down 23.76% from the prior year.
• Capital Leases for Q1 2022 stood at $1.8 million, down from $1.9 million in the prior quarter.
• Over the last five years, Capital Leases for RYTM reached as high as $3.4 million in Q1 2019 and fell as low as $1.8 million in Q1 2022.
• Historically, Capital Leases has averaged $2.6 million across 4 years, with a median of $2.6 million in 2020.
• Across the five-year window, Capital Leases fell 15.1% in 2020 and dropped 25.98% in 2022, its largest moves.
• Year by year, Capital Leases stood at $3.1 million in 2019, then slipped by 17.34% to $2.6 million in 2020, then declined by 23.76% to $1.9 million in 2021, then dropped by 8.43% to $1.8 million in 2022.
• Per Business Quant data, the three most recent Capital Leases figures were $1.8 million in Q1 2022, $1.9 million in Q4 2021, and $2.1 million in Q3 2021.